Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2020 | Migraine: CGRP mAbs efficacy measured over time

Dagny Holle-Lee, MD, PhD, Essen University Hospital, Essen, Germany, talks on monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) an how patients can benefit from their effects within the first weeks of treatment. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).